Obesity Drug
- All
- News
- Videos
-
New Experimental Obesity Drugs Target Mitochondria To Burn More Calories: Australian Study
The team, led by researchers from the University of Technology Sydney in Australia, focussed on "mitochondrial uncouplers" - molecules that make cells burn energy less efficiently and release fuel as heat instead of converting it into energy the body
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Hack It, Don't Work Hard: Does The Craze Around Ozempic Indicate India's Future Drug Dependency Over Holistic Wellness?
GLP-1s were originally developed to manage diabetes by lowering blood sugar levels. However, the additional benefit of weight loss has gained more attention than their primary function of controlling
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Weight Loss Drugs In India: The Rise Of GLP-1s In 2025
GLP-1 receptor agonists mimic the action of the glucagon-like peptide-1 hormone, which is involved in the regulation of appetite and insulin secretion. When administered, these medications stimulate insulin production.
-
Ozempic Too Costly? 7 Cheaper And Clinically Approved Alternatives Available In India
Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives which can also aid in weight loss?
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
'Ozempic' For Cats: Vets Test Weight-Loss Drug On Overweight Felines
Modeled after Ozempic, the treatment offers hope for pet owners struggling to manage feline obesity and its related health risks.
-
"Medication Alone Won't Reverse Obesity": WHO Issues Guidelines On GLP-1 Drugs
The WHO guideline emphasises that medicines alone will not solve the problem.Addressing obesity requires a comprehensive approach.
-
Obesity: Why New Medications Are Not Miracle Cures
Recently, new drugs - analogs of the gut hormone glucagon-like peptide-1 (GLP-1) have been added to the therapeutic arsenal, raising new hopes. However, they alone will not be enough to conquer obesity.
-
Opinion | The Rich Get Fit, And Poor Get 'Lectures' - That's India's Ozempic Problem
Ozempic has arrived in India - and so has the moral panic around it.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg Intelligence estimates will reach $100 billion in annual sales by 2030.
-
Higher Doses Of Semaglutide Safe, Can Aid In Better Weight Loss For Obese Adults: Study
A study published in The Lancet Diabetes & Endocrinology journal, suggest that a higher dose of semaglutide offers a promising new option for people who have not achieved sufficient weight loss with existing treatments.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
New Experimental Obesity Drugs Target Mitochondria To Burn More Calories: Australian Study
The team, led by researchers from the University of Technology Sydney in Australia, focussed on "mitochondrial uncouplers" - molecules that make cells burn energy less efficiently and release fuel as heat instead of converting it into energy the body
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Hack It, Don't Work Hard: Does The Craze Around Ozempic Indicate India's Future Drug Dependency Over Holistic Wellness?
GLP-1s were originally developed to manage diabetes by lowering blood sugar levels. However, the additional benefit of weight loss has gained more attention than their primary function of controlling
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Weight Loss Drugs In India: The Rise Of GLP-1s In 2025
GLP-1 receptor agonists mimic the action of the glucagon-like peptide-1 hormone, which is involved in the regulation of appetite and insulin secretion. When administered, these medications stimulate insulin production.
-
Ozempic Too Costly? 7 Cheaper And Clinically Approved Alternatives Available In India
Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives which can also aid in weight loss?
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
'Ozempic' For Cats: Vets Test Weight-Loss Drug On Overweight Felines
Modeled after Ozempic, the treatment offers hope for pet owners struggling to manage feline obesity and its related health risks.
-
"Medication Alone Won't Reverse Obesity": WHO Issues Guidelines On GLP-1 Drugs
The WHO guideline emphasises that medicines alone will not solve the problem.Addressing obesity requires a comprehensive approach.
-
Obesity: Why New Medications Are Not Miracle Cures
Recently, new drugs - analogs of the gut hormone glucagon-like peptide-1 (GLP-1) have been added to the therapeutic arsenal, raising new hopes. However, they alone will not be enough to conquer obesity.
-
Opinion | The Rich Get Fit, And Poor Get 'Lectures' - That's India's Ozempic Problem
Ozempic has arrived in India - and so has the moral panic around it.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg Intelligence estimates will reach $100 billion in annual sales by 2030.
-
Higher Doses Of Semaglutide Safe, Can Aid In Better Weight Loss For Obese Adults: Study
A study published in The Lancet Diabetes & Endocrinology journal, suggest that a higher dose of semaglutide offers a promising new option for people who have not achieved sufficient weight loss with existing treatments.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
